Education
About Us
Working with TipRanks
Follow Us
FTXH - ETF AI Analysis
Top Page
First Trust Nasdaq Pharmaceuticals ETF (FTXH)
Rating:73Outperform
Price Target:―
Positive Factors
Leading Pharma Blue-Chip Holdings
The ETF’s largest positions include well-known, financially strong pharmaceutical companies that have generally shown steady to strong performance this year.
Recent Performance Momentum
The fund has delivered solid gains over the last three months, indicating improving short-term momentum despite a slightly weak recent one-month period.
Focused Exposure to U.S. Health Care
Almost all assets are invested in U.S. health care stocks, giving targeted exposure to a defensive sector that can be more resilient in economic slowdowns.
Negative Factors
High Sector Concentration
With nearly all assets in the health care sector, the ETF is heavily exposed to industry-specific risks such as regulatory changes and drug pricing pressures.
Mixed Performance Among Top Holdings
Several major positions have shown weak or negative performance this year, which can drag on overall returns if those stocks do not recover.
Above-Average Expense Ratio
The fund’s management fee is relatively high for an ETF, which can slowly reduce investors’ net returns over time.
FTXH vs. SPDR S&P 500 ETF (SPY)
AUM28.07M
RegionNorth America
Expense Ratio0.60%
Beta0.56
IssuerFirst Trust
Inception DateSep 20, 2016
Dividend Yield1.32%
Asset ClassEquity
Index TrackedNasdaq US Smart Pharmaceuticals Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume18,722
30 Day Avg. Volume7,442
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
39.07Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FTXH Summary
FTXH is the First Trust Nasdaq Pharmaceuticals ETF, which follows the Nasdaq US Smart Pharmaceuticals Index. It invests mainly in U.S. drugmakers and health care companies, from large, well-known names like Merck and Johnson & Johnson to other firms focused on developing new medicines. Someone might consider this ETF if they want targeted exposure to the potential growth of the pharmaceutical industry and prefer a basket of stocks instead of picking individual companies. A key risk is that it is heavily focused on one sector, so its price can swing with changes in drug approvals, regulation, and health care policy.
How much will it cost me?The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it is actively managed and focuses on a specialized sector, which typically involves more research and management costs.
What would affect this ETF?The FTXH ETF could benefit from advancements in pharmaceutical research, including breakthroughs in drug development and personalized medicine, as well as increased demand for innovative health care solutions in the U.S. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact the profitability of its top holdings like AbbVie, Johnson & Johnson, and Merck.
FTXH Top 10 Holdings
FTXH is very much a U.S. big-pharma story, with heavyweights like Merck, Johnson & Johnson, and Bristol-Myers Squibb doing the heavy lifting as their shares have been steadily rising on solid earnings and healthy pipelines. Viatris has been a surprise bright spot, sprinting ahead and adding extra fuel to recent returns despite lingering financial questions. On the flip side, AbbVie looks a bit wobbly and Eli Lilly is losing steam after a strong run, tempering some of the upside. Overall, this is a concentrated bet on U.S. pharmaceutical powerhouses.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Merck & Company | 8.44% | $2.36M | $301.96B | 36.60% | 80 Outperform | |
| Johnson & Johnson | 7.95% | $2.23M | $590.40B | 49.41% | 78 Outperform | |
| Bristol-Myers Squibb | 7.47% | $2.09M | $121.64B | 8.65% | 78 Outperform | |
| Pfizer | 6.25% | $1.75M | $155.62B | 1.33% | 74 Outperform | |
| AbbVie | 6.20% | $1.74M | $404.24B | 11.25% | 66 Neutral | |
| Viatris | 4.38% | $1.23M | $18.49B | 41.51% | 60 Neutral | |
| Cardinal Health | 4.38% | $1.23M | $52.94B | 76.64% | 66 Neutral | |
| Biogen | 4.14% | $1.16M | $28.49B | 36.54% | 74 Outperform | |
| Eli Lilly & Co | 4.00% | $1.12M | $962.75B | 15.55% | 72 Outperform | |
| Regeneron | 3.90% | $1.09M | $83.73B | 11.33% | 78 Outperform |
FTXH Technical Analysis
Positive
―
Price Trends
33.72
Positive
32.04
Positive
29.15
Positive
Market Momentum
0.45
Positive
60.16
Neutral
63.51
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FTXH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 34.58, equal to the 50-day MA of 33.72, and equal to the 200-day MA of 29.15, indicating a bullish trend. The MACD of 0.45 indicates Positive momentum. The RSI at 60.16 is Neutral, neither overbought nor oversold. The STOCH value of 63.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTXH.
FTXH Peer Comparison
Comparison Results
Performance Comparison
FTXH
First Trust Nasdaq Pharmaceuticals ETF
35.01
7.20
25.89%
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
XHS
SPDR S&P Health Care Services ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents